

Corresponding author(s): Meritxell Genescà NCOMMS-19-03831

Last updated by author(s): Sep 20, 2019

# **Reporting Summary**

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

Statistics			
For all statistical analys	es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.		
n/a Confirmed			
☐ ☐ The exact sam	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement		
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly			
The statistical test(s) used AND whether they are one- or two-sided  Only common tests should be described solely by name; describe more complex techniques in the Methods section.			
A description	A description of all covariates tested		
A description	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons		
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)			
For null hypot	thesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted is exact values whenever suitable.		
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings			
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes			
Estimates of e	effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated		
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.		
Software and o	code		
Policy information abo	ut <u>availability of computer code</u>		
Data collection	No software used.		
Data analysis	We used GraphPad Prism (version 7.0) for statistical analysis. For flow cytometry analysis we used FlowJo vX.0.7 (TreeStar), for flow imaging analysis IDEAS v6.1 and for microscopy images analysis ImageJ 1.50i.		
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.			
Data			
- Accession codes, un - A list of figures that	ut <u>availability of data</u> include a <u>data availability statement</u> . This statement should provide the following information, where applicable: ique identifiers, or web links for publicly available datasets have associated raw data restrictions on data availability		
There are no restriction f	or any materials used in this study.		
Field-speci	fic reporting		
Please select the one b	elow that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
M Life sciences	Pohavioural & social sciences		

# Life sciences study design

Recruitment

obtained for this study.

All studies must dis	close on these	e points even when the disclosure is negative.	
Sample size	No sample-size calculations were performed. Based on tissue availability, sample size was determined to be adequate based on the magnitude and consistency of measurable differences between groups.		
Data exclusions	Two samples lacking epithelial tissue in the cervical slide were excluded for the ISH/IHC analysis.		
Replication	Replicate expe	eriments were successful.	
Randomization	Randomization was not relevant to this study.		
Blinding	Analyses were	eunblinded	
Reportin	g for s	pecific materials, systems and methods	
		s about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, o your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.	
Materials & exp	perimental	systems Methods	
n/a Involved in th	ie study	n/a Involved in the study	
Antibodies		ChIP-seq	
Eukaryotic	cell lines	Flow cytometry	
Palaeontolo	ntology MRI-based neuroimaging		
Animals an	d other organis	ms	
Human res	earch participa	nts	
Clinical dat	a		
Antibodies			
Antibodies used	A	All antibodies used in this study are detailed in material and methods section.	
Validation All a		All antibodies are commercially available and were commercially validated.	
Eukaryotic c	ell lines		
Policy information			
,			
Cell line source(s)	)	J-Lat9.2 cells were obtained from the AIDS Reagent Bank.	
Authentication		No authentication was performed.	
Mycoplasma conf	tamination	J-Lat9.2 cells were negative for mycoplasma contamination.	
Commonly miside (See <u>ICLAC</u> register)		No commonly misidentified cell lines were used.	
Human rese	arch part	icipants	
		involving human research participants	
Population chara	cteristics   F	HIV- women undergoing non-neoplastic hysterectomies provided cervical tissue for this study (range 26-74 years old). Information about the characteristics of the HIV+ women included in this study is detailed in Table 1. Basically all HIV+ patients were ART-treated with undetectable viral load (< 50copies HIV-RNA/ml plasma), except for one patient with detectable viral load (> 50 copies HIV-RNA/ml plasma).	

HIV+ and HIV- donors were recruited based on surgical planification. Women undergoing non-neoplastic hysterectomies were

recruited by collaborating gynecologists at Hospital Universitari Vall d'Hebron (HUVH) in Barcelona, Spain. HIV+ women undergoing a hysterectomy or a cone biopsy at the HUVH, at the Germans Trias i Pujol University Hospital (HUGTP) or at the Parc de Salut Mar (Barcelona, Spain) were also recruited by collaborating gynecologists, in which a coded blood sample was also

Ethics oversight

Study protocols were approved by the corresponding Institutional Review Board (numbers PR (IR)294/2017 for the HUVH, PI-17-159 for the HUGTP and 2018/8017/I for the Parc de Salut Mar) and written informed consent was provided by all patients recruited to this study.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

### Flow Cytometry

#### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

### Methodology

Sample preparation

PBMC were isolated by Ficoll density gradient centrifugation and stained as indicated in materials and methods section. Cervical tissue was digested with an appropriated protocol (indicated in materials and methods section), stained with viability dye, then stained with indicated antibodies and resuspended either in 1X PBS-2%FBS-1mM EDTA for sorting or in 1% paraformaldehyde for fix it before acquisition on an analyzer.

Instrument

BD FACS Fortessa analyzer, BD FACS Aria sorter, BD FACS Calibur analyzer and an Amnis® ImageStreamx.

Software

FACS Diva and CellQuest for data collection. FlowJo and IDEAS software for data analysis.

Cell population abundance

No tests were performed to asses the purity of each population after sorting.

Gating strategy

All samples were initially gated using forward scatter and side scatter to identify events corresponding to cells or, alternatively by CD45 and side scatter to identify events corresponding to hemapoietic cells, and then using forward scatter height vs. area and side scatter height vs. area to enrich for single cells, next alive cells were selected by negativity for viability dye. The follow gating steps are presented in principal and supplementary figures.

| Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.